Academic medical centers in the US are voicing concern over reduced funding from the National Institutes of Health (NIH). While the issue is domestic, its effects may be global.
These institutions are key drivers of innovation far beyond the US, often laying the foundation for diagnostics, AI in healthcare, and advanced imaging breakthroughs. When public funding slows, private innovation can follow — across borders.
At Axcellant, we closely follow these developments, recognizing how early-stage research shapes the future of clinical advancements worldwide.
Explore how we support global innovation through smarter trial strategies.
Axcellant participated in the PET Symposium 2025, held in Turku, marking 50 years of PET radiochemistry at the Turku PET…
The EU is moving forward with key upgrades to its medical device and diagnostics regulations, specifically under the Medical Device…
Gene therapies now account for most ATMP clinical trials, with a balanced distribution between in vivo and ex vivo approaches.…
Copyright @ 2025 Axcellant